Positive results for AZ’s type 2 diabetes trial

AstraZeneca has reported positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) of BMS-512148 compared to placebo for the treatment of patients with type 2 diabetes (T2D). The trial had met its primary safety objective of non-inferiority for major adverse cardiovascular events (MACE). The trial also achieved one of its two

Continue Reading

Lilly commences plaque psoriasis treatment head to head trial

Eli Lilly and Company (Lilly) has commenced the IXORA-R head-to-head (H2H) clinical trial to investigate the efficacy and safety of ixekizumab when compared to guselkumab to treat adult patients with moderate-to-severe plaque psoriasis. Roughly 960 patients are expected to be included in the 24-week, multicentre, randomised, blinded, parallel-group trial. The trial’s primary objective is the

Continue Reading

Enrolment completed for phase 3 of Horizon’s Tyroid eye disease trial

Horizon Pharma has stated that their Phase III trial of teprotumumab in patients living with moderate-to-severe active thyroid eye disease (TED) has completed enrolment ahead of schedule. TED is a rare autoimmune disease where the insulin-like growth factor receptor (IGF-1R) is overexpressed on eye tissues, which then leads to local inflammation, orbital fibroblast proliferation and

Continue Reading

Clinical trials specialists: researchers of the future

Clinical Professionals are proud to be part of 2 trailblazer groups working on apprenticeship standards for clinical trials and regulatory affairs – now officially moving forward! More than 2,500 employers have developed apprenticeship standards, creating new opportunities and specialist on-the-job training programmes for the workforce of the future. The Clinical Trials Specialist Apprenticeship was the

Continue Reading